# **ECAT FOUNDATION**

# **External quality Control for Assays and Tests**

With a focus on Thrombosis and Haemostasis

# **REPORT**



SURVEY 2025-H2 Haemophilia Labcode 1492

Copyright © 2025 ECAT Foundation



Version:

1.0.0

Survey: 2025-H2 Page 2 of 16 14-July-2025

Labcode: 1492

Date of Issue : 14-July-2025

Survey : 2025-H2

Report : Haemophilia

#### Note:

In the Survey Manual 2025 detailed information is given regarding the ECAT external quality assessment programme, including the statistical evaluation and explanation of the report.

This Survey Manual 2025 should be considered as an integral part of this survey report.

Please notice the information regarding the homogeneity of samples used and the between-laboratory variation in the paragraph on the statistical evaluation of the Survey Manual.

#### **General Information**

#### **Exclusion of results**

Results < [value] or > [value] are excluded from the statistical analysis. When other results (e.g. deviating results) are excluded from the statistical analysis, these results are placed between brackets.

### Multiple instruments

From 2019 you have the possibility to submit per parameter results for three different instruments and or methods. However, some participants have submitted three times the same results, suggesting that this are separate results. This is not the case and may affect the statistical analysis. We have excluded the results from the second and third test system from the statistical analysis. Do not submit multiple times the same results anymore in future surveys.

#### **Complaints**

Any complaints regarding this survey report should be reported to the ECAT before: **September 23rd, 2025.** Complaints received after this date will not be taken into consideration.

This report is authorized by: Dr.P.Meijer (Director)

<u>Note</u>: The current Survey Manual can be downloaded from the 'Participant Area' of the ECAT website. Login and select the option 'View Documents'.

**ECAT** Foundation

Director: Dr. P. Meijer
ECAT Office
P.O. Box 107
2250 AC Voorschoten, The Netherlands
phone +31 (0) 71 3030 910; fax + 31 (0) 71 3030 919
E-mail: info@ecat.nl
Website: www.ecat.nl
VAT number: NL802836872B01

Registration number with the Chamber of Commerce (KvK) Gouda : 41174102 General terms of delivery are applicable to all our services



Survey: 2025-H2

Page 3 of 16 14-July-2025

Labcode: 1492

### **OVERVIEW Z-SCORES**

1.0.0

Version:

UV:Satisfactory (-2 ≤ Z-score ≤ 2)

UV: Need attention (-3 < Z-score < -2 or 2 < Z-score < 3)

UV:Unsatisfactory (Z-score ≤ -3 or ≥ 3) BV: Unacceptable

									Bivarate
Module	Parameter	Sample	Test System	Total	,	Assay	M	lethod	Analysis
Factor VIII inhibitor	Factor VIII Inhibitor (by type of test)	25.115	1	0.32		0.39			
		25.116	1	0.02		0.10			
Factor VIII inhibitor	Factor VIII Inhibitor (by assay concept)	25.115	1	0.32		0.36		0.06	
		25.116	1	0.02		0.11		-0.09	
Factor VIII inhibitor	Factor VIII Inhibitor (by FVIII assay)	25.115	1	0.32		1.08		1.35	
		25.116	1	0.02		0.75		0.86	



Survey: 2025-H2 Page 4 of 16

Page 4 of 16 14-July-2025

1492

Labcode:

### **Factor VIII inhibitor**

### Factor VIII Inhibitor (by type of test)

Version:

1.0.0

**Sample No** 25.115

Sample Details Plasma with a Factor VIII Inhibitor level of approx. 25.0 BU/mL

Prior Use None Unit BU/mL

Expiry Date 31-January-2028

Homogeneity 3.9 % Homogeneity Parameter Factor VIII Inhibitor

For any method used for the measurement of this parameter with a CV ≤ 13.0% the criterion for

homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details

the paragraph on the statistical evaluation in the Survey Manual.

Number of Participants 343

Number of Responders 320 Response Rate 93 %

Comments The following participants reported deviating results which were excluded from the statistical analysis:

102: 1.2 BU/mL3606: 0.4 BU/mL6222: 160 BU/mL3855: 89 BU/mL

Participants **610** and **1180** reported deviating results which were excluded from the statistical analysis. These results might be caused by an accidental mix-up of the sample 25.115 and 25.116.


Participant **3828** has submitted three times the same result, suggesting that these are separate results. This is not the case and may affect the statistical analysis and therefore the second and third result were excluded.

	lassification verview	No classification	Negative	Equivocal	Positive
1	Гotal	1	3	0	358

Your Classification Positive

Own Reagent											
	n	assigned	Uncert.	CV (%)	Range	your	z-score	your	z-score	your	z-score
		value				result		result		result	
Total Group	356	22.9	0.44	29.4	4.3 - 57.8	25.0	0.32				
Lab-developed test	243	22.5	0.52	28.6	9.0 - 57.8	25.0	0.39				

	n	assigned value	Uncert.	CV (%)	Range
Total Group	356	22.9	0.44	29.4	4.3 - 57.8
Commercial Test	113	23.7	0.86	30.8	4.3 - 48.0
Other	59	21.7	1.22	34.5	4.3 - 48.0
Precision Biologics	22	22.2	1.45	24.5	14.0 - 35.6
Technoclone	32	28.1	1.14	18.4	17.0 - 35.3
Lab-developed test	243	22.5	0.52	28.6	9.0 - 57.8





Survey: 2025-H2

Page 5 of 16 14-July-2025

Labcode: 1492

### **Factor VIII inhibitor**

### Factor VIII Inhibitor (by type of test)

Version:

1.0.0

**Sample No** 25.116

Sample Details Plasma with a Factor VIII Inhibitor level of approx. 6.0 BU/mL

Prior Use None Unit BU/mL

Expiry Date 31-January-2028

Homogeneity 4.0 % Homogeneity Parameter Factor VIII Inhibitor

For any method used for the measurement of this parameter with a CV ≤ 13.3% the criterion for

homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details

the paragraph on the statistical evaluation in the Survey Manual.

Number of Participants 343

Number of Responders 320 Response Rate 93 %

Comments The following participants reported deviating results which were excluded from the statistical analysis:

 126:
 52.5
 BU/mL

 1425:
 38.40
 BU/mL

 3855:
 38
 BU/mL

 3606:
 0.0
 BU/mL

Participants **610** and **1180** reported deviating results which were excluded from the statistical analysis. These results might be caused by an accidental mix-up of the sample 25.115 and 25.116.


Participant **3828** has submitted three times the same result, suggesting that these are separate results. This is not the case and may affect the statistical analysis and therefore the second and third result were excluded.

Classification Overview	No classification	Negative	Equivocal	Positive
Total	1	4	4	351

Your Classification Positive


Own Reagent	wn Reagent										
	n	assigned	Uncert.	CV (%)	Range	your	z-score	your	z-score	your	z-score
		value				result		result		result	
Total Group	358	5.3	0.09	25.9	1.1 - 11.4	5.3	0.02				
Lab-developed test	245	5.2	0.10	25.4	1.1 - 11.4	5.3	0.10				

	n	assigned value	Uncert.	CV (%)	Range
Total Group	358	5.3	0.09	25.9	1.1 - 11.4
Commercial Test	113	5.5	0.17	26.7	2.7 - 8.4
Other	58	5.1	0.23	28.2	2.7 - 8.4
Precision Biologics	23	5.0	0.26	19.8	3.4 - 6.6
Technoclone	32	6.5	0.23	15.9	3.8 - 8.2
Lab-developed test	245	5.2	0.10	25.4	1.1 - 11.4



1.0.0 Version:

Survey: 2025-H2 Page 6 of 16 14-July-2025





Survey: 2025-H2

Page 7 of 16 14-July-2025

Version: 1.0.0 Labcode: 149

### **Factor VIII inhibitor**

### Factor VIII Inhibitor (by assay concept)

**Sample No** 25.115

Sample Details Plasma with a Factor VIII Inhibitor level of approx. 25.0 BU/mL

Prior Use None Unit BU/mL

Expiry Date 31-January-2028

Homogeneity 3.9 % Homogeneity Parameter Factor VIII Inhibitor

For any method used for the measurement of this parameter with a CV ≤ 13.0% the criterion for

homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details

the paragraph on the statistical evaluation in the Survey Manual.

Number of Participants 343

Number of Responders 320 Response Rate 93 %

Comments The following participants reported deviating results which were excluded from the statistical analysis:

102: 1.2 BU/mL3606: 0.4 BU/mL6222: 160 BU/mL3855: 89 BU/mL

Participants **610** and **1180** reported deviating results which were excluded from the statistical analysis. These results might be caused by an accidental mix-up of the sample 25. 115 and 25.116.

Own Reagent	<u>Dwn Reagent</u>										
	n	assigned value	Uncert.	CV (%)	Range	your result	z-score	your result	z-score	your result	z-score
Total Group	356	22.9	0.44	29.4	4.3 - 57.8	25.0	0.32				
Buffered Normal Pooled Plasma	260	22.5	0.53	30.1	4.3 - 57.8	25.0	0.36				
Buffer	107	24.7	0.74	24.8	15.0 - 57.8	25.0	0.06				




Version: 1.0.0


Survey: 2025-H2 Page 8 of 16

14-July-2025

Labcode: 1492

	n	assigned value	Uncert.	CV (%)	Range
Total Group	356	22.9	0.44	29.4	4.3 - 57.8
Non-Buffered Normal Pooled Plasma	95	23.7	0.83	27.2	10.6 - 48.0
Buffer	55	23.4	0.99	25.2	12.0 - 35.3
Buffer + Albumin	2	26.3			22.5 - 30.1
Factor VIII Deficient Plasma	23	22.5	2.12	36.1	10.6 - 36.1
Heat-activated normal plasma	2	35.1			22.2 - 48.0
Other	12	25.7	1.99	21.5	16.6 - 35.2
Unknown	1	29.0			-
Buffered Normal Pooled Plasma	260	22.5	0.53	30.1	4.3 - 57.8
Buffer + Albumin	24	24.1	1.91	31.0	14.0 - 37.1
Factor VIII Deficient Plasma	96	19.6	0.84	33.5	4.3 - 35.6
Heat-inactivated normal plasma	17	21.7	2.36	35.9	9.0 - 38.3
Other	14	23.7	1.73	21.9	17.0 - 33.5
Unknown	2	22.9			18.9 - 26.8
Unknown	1	24.5			-
Buffer	1	24.5			-







Survey: 2025-H2

Page 9 of 16 14-July-2025

Version: 1.0.0 Labcode: 1492

### **Factor VIII inhibitor**

### Factor VIII Inhibitor (by assay concept)

**Sample No** 25.116

Sample Details Plasma with a Factor VIII Inhibitor level of approx. 6.0 BU/mL

Prior Use None Unit BU/mL

Expiry Date 31-January-2028

Homogeneity 4.0 % Homogeneity Parameter Factor VIII Inhibitor

For any method used for the measurement of this parameter with a CV ≤ 13.3% the criterion for

homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details

the paragraph on the statistical evaluation in the Survey Manual.

Number of Participants 343

Number of Responders 320 Response Rate 93 %

Comments

The following participants reported deviating results which were excluded from the statistical analysis:

 126:
 52.5
 BU/mL

 1425:
 38.40
 BU/mL

 3855:
 38
 BU/mL

 3606:
 0.0
 BU/mL

Participants **610** and **1180** reported deviating results which were excluded from the statistical analysis. These results might be caused by an accidental mix-up of the sample 25. 115 and 25.116.

Own Reagent	wn Reagent										
	n	assigned value	Uncert.	CV (%)	Range	your result	z-score	your result	z-score	your result	z-score
								resuit		resuit	
Total Group	358	5.3	0.09	25.9	1.1 - 11.4	5.3	0.02				
Buffered Normal Pooled Plasma	262	5.2	0.10	25.3	1.1 - 9.8	5.3	0.11				
Buffer	109	5.4	0.15	23.1	2.5 - 8.4	5.3	-0.09				





Version: 1.0.0

Survey: 2025-H2 Page 10 of 16 14-July-2025

Labcode: 1492


	n	assigned	Uncert.	CV (%)	Range
		value			
Total Group	358	5.3	0.09	25.9	1.1 - 11.4
Non-Buffered Normal Pooled Plasma	95	5.6	0.19	26.0	2.7 - 11.4
Buffer	55	5.5	0.23	25.1	2.7 - 8.5
Buffer + Albumin	2	5.8			4.8 - 6.9
Factor VIII Deficient Plasma	24	5.4	0.41	30.0	3.1 - 8.5
Heat-activated normal plasma	2	5.9			5.4 - 6.4
Other	11	6.5	0.94	38.1	3.8 - 11.4
Unknown	1	6.0			-
Buffered Normal Pooled Plasma	262	5.2	0.10	25.3	1.1 - 9.8
Buffer + Albumin	25	5.4	0.32	23.6	3.4 - 9.8
Factor VIII Deficient Plasma	96	4.7	0.16	26.8	1.1 - 8.0
Heat-inactivated normal plasma	17	5.6	0.49	28.8	3.4 - 8.2
Other	13	5.4	0.25	13.2	4.6 - 8.0
Unknown	2	6.7			6.5 - 6.9
Unknown	1	5.0			-
Buffer	1	5.0			-





1.0.0 Version:

Survey: 2025-H2 Page 11 of 16 14-July-2025





Survey: 2025-H2 Page 12 of 16 14-July-2025

Version: 1.0.0 Labcode: 14

### **Factor VIII inhibitor**

### Factor VIII Inhibitor (by FVIII assay)

**Sample No** 25.115

Sample Details Plasma with a Factor VIII Inhibitor level of approx. 25.0 BU/mL

Prior Use None Unit BU/mL

Expiry Date 31-January-2028

Homogeneity 3.9 % Homogeneity Parameter Factor VIII Inhibitor

For any method used for the measurement of this parameter with a CV ≤ 13.0% the criterion for

homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details

the paragraph on the statistical evaluation in the Survey Manual.

Number of Participants 343

Number of Responders 320 Response Rate 93 %

Comments The following participants reported deviating results which were excluded from the statistical analysis:

102: 1.2 BU/mL3606: 0.4 BU/mL6222: 160 BU/mL3855: 89 BU/mL

Participants **610** and **1180** reported deviating results which were excluded from the statistical analysis. These results might be caused by an accidental mix-up of the sample 25. 115 and 25.116.

Own Reagent											
	n	assigned value	Uncert.	CV (%)	Range	your result	z-score	your result	z-score	your result	z-score
Total Group	356	22.9	0.44	29.4	4.3 - 57.8	25.0	0.32	roourt		Toodit	
Chromogenic assay	63	20.2	0.70	22.1	11.9 - 29.3	25.0	1.08				
Siemens Factor VIII	28	18.8	1.09	24.6	11.9 - 29.3	25.0	1.35				




Version: 1.0.0


Survey: 2025-H2 Page 13 of 16

14-July-2025

Labcode: 1492

	n	assigned value	Uncert.	CV (%)	Range
Total Group	356	22.9	0.44	29.4	4.3 - 57.8
One-stage clotting assay	293	23.5	0.51	29.9	4.3 - 57.8
Hemoliance Synthasil APTT	1	18.2			-
Hyphen Biomed Cephen	1	20.4			-
Roche APTT	1	31.2			-
Siemens Actin FS	48	20.4	1.14	31.0	10.9 - 35.2
Siemens Actin FSL	11	25.3	3.21	33.7	9.0 - 35.6
Siemens Pathromtin SL	32	23.3	1.40	27.3	11.9 - 38.3
Stago Cephalin/Kaolin/CK Prest	56	23.6	1.13	28.6	8.0 - 36.1
Stago PTT (automate)	9	22.0			16.0 - 57.8
Tcoag TriniClot APTT S	1	18.6			-
Tcoag TriniClot APTT-HS	2	23.6			21.1 - 26.0
Technoclone Dapttin	1	22.1			-
Werfen HemosIL APTT-SP liquid silica	2	17.5			16.5 - 18.4
Werfen HemosIL SynthASil	123	24.7	0.80	28.7	4.3 - 48.0
Chromogenic assay	63	20.2	0.70	22.1	11.9 - 29.3
Chromogenix Coamatic Factor VIII	14	21.5	1.10	15.3	16.8 - 27.0
Chromogenix Coatest SP Factor VIII	1	18.0			-
Hyphen Biomed Biophen Factor VIII	1	16.0			-
Other	3	15.6			13.1 - 22.3
Precision Biologic Cryocheck Chromog	7	19.5			16.4 - 24.5
TCoag Trinichrom FVIII	1	16.5			-
Technocione Factor VIII	2	23.7			20.9 - 26.4
Werfen Electrachrome FVIII	6	24.6			22.6 - 28.3









Survey: 2025-H2 Page 14 of 16 14-July-2025

Version: 1.0.0 Labcode: 1493

### **Factor VIII inhibitor**

### Factor VIII Inhibitor (by FVIII assay)

Sample No 25.116

Sample Details Plasma with a Factor VIII Inhibitor level of approx. 6.0 BU/mL

Prior Use None Unit BU/mL

Expiry Date 31-January-2028

Homogeneity 4.0 % Homogeneity Parameter Factor VIII Inhibitor

For any method used for the measurement of this parameter with a CV ≤ 13.3% the criterion for

homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details

the paragraph on the statistical evaluation in the Survey Manual.

Number of Participants 343

Number of Responders 320 Response Rate 93 %

Comments

The following participants reported deviating results which were excluded from the statistical analysis:

 126:
 52.5
 BU/mL

 1425:
 38.40
 BU/mL

 3855:
 38
 BU/mL

 3606:
 0.0
 BU/mL

Participants **610** and **1180** reported deviating results which were excluded from the statistical analysis. These results might be caused by an accidental mix-up of the sample 25. 115 and 25.116.

Own Reagent											
	n	assigned value	Uncert.	CV (%)	Range	your result	z-score	your result	z-score	your result	z-score
Total Group	358	5.3	0.09	25.9	1.1 - 11.4	5.3	0.02				
Chromogenic assay	64	4.7	0.13	17.8	3.4 - 7.4	5.3	0.75				
Siemens Factor VIII	29	4.5	0.21	20.0	3.4 - 6.5	5.3	0.86				




Version: 1.0.0


Survey: 2025-H2 Page 15 of 16 14-July-2025

Labcode: 1492

	n	assigned value	Uncert.	CV (%)	Range	
Total Group	358	5.3	0.09	25.9	1.1 - 11.4	
One-stage clotting assay	294	5.4	0.10	26.6	1.1 - 11.4	
Hemoliance Synthasil APTT	1	5.1			-	
Hyphen Biomed Cephen	1	5.2			-	
Roche APTT	1	6.4			-	
Siemens Actin FS	49	4.9	0.22	24.8	3.1 - 8.0	
Siemens Actin FSL	11	6.2	0.55	23.5	4.4 - 8.0	
Siemens Pathromtin SL	32	5.4	0.36	30.0	2.7 - 8.2	
Stago Cephalin/Kaolin/CK Prest	56	5.4	0.23	25.7	2.7 - 11.4	
Stago PTT (automate)	10	5.2	0.25	12.1	4.2 - 6.1	
Tcoag TriniClot APTT S	1	4.3			-	
Tcoag TriniClot APTT-HS	2	4.9			4.7 - 5.0	
Technoclone Dapttin	1	5.0			-	
Werfen HemosIL APTT-SP liquid silica	2	4.8			4.1 - 5.5	
Werfen HemosIL SynthASiI	121	5.6	0.17	27.1	1.8 - 9.8	
Chromogenic assay	64	4.7	0.13	17.8	3.4 - 7.4	
Chromogenix Coamatic Factor VIII	13	4.8	0.25	14.9	4.0 - 7.4	
Chromogenix Coatest SP Factor VIII	1	4.0			-	
Hyphen Biomed Biophen Factor VIII	1	4.2			-	
Other	3	4.0			3.4 - 4.4	
Precision Biologic Cryocheck Chromog	8	4.7			4.0 - 5.4	
TCoag Trinichrom FVIII	1	4.6			-	
Technoclone Factor VIII	2	5.1			4.8 - 5.3	
Werfen Electrachrome FVIII	6	5.4			5.3 - 7.2	







1.0.0 Version:

Survey: 2025-H2 Page 16 of 16 14-July-2025

